drugset / Trial / NCT02549040

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

NCT02549040

Phase 1 Completed 16 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate and compare the relative bioavailability of different doravirine (MK-1439) experimental nano formulations (NFs) with that of a doravirine film coated tablet.

Timeline

Start
2015-09-21
Primary completion
2015-12-24
Completion
2015-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Doravirine Small molecule 100 mg Oral
Subject Doravirine Small molecule 150 mg Oral